Results 211 to 220 of about 54,424 (260)

Cost-effectiveness of ceftolozane/tazobactam compared to meropenem in ventilator-associated pneumonia. [PDF]

Cost Eff Resour Alloc
Buendía JA, Patiño DG, Zuluaga Salazar AF.   +2 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Ventilator-associated pneumonia

Current Opinion in Anaesthesiology, 2002
Ventilator-associated pneumonia is the most serious infectious complication in critically ill patients, associated with increased length of intensive care unit treatment and high mortality rates. Investigations focused on outcome variables have improved the database to estimate diagnostic and therapeutic management strategies.
Alexandra, Heininger, Wolfgang A, Krueger, Gerd, Doring, Klaus, Unertl   +3 more
openaire   +4 more sources

Ventilator-associated pneumonia

International Journal of Antimicrobial Agents, 1998
Mechanically ventilated patients are at a substantially higher risk for developing nosocomial pneumonia. Overall, there is a relatively constant 1&!TN!150;3% risk per day of developing pneumonia while receiving mechanical ventilation. The sensitivity and specificity of clinical criteria alone for diagnosis of ventilator-associated pneumonias (VAP) is ...
F, Visnegarwala, N G, Iyer, R J, Hamill
openaire   +2 more sources

Ventilator Associated Pneumonia in Children

Paediatric Respiratory Reviews, 2016
Ventilator associated pneumonia (VAP) is a common complication in mechanically ventilated children and adults. There remains much controversy in the literature over the definition, treatment and prevention of VAP. The incidence of VAP is variable, depending on the definition used and can effect up to 12% of ventilated children.
Chang, Ivy, Schibler, Andreas
openaire   +5 more sources

Biofilms in Ventilator-Associated Pneumonia

Future Microbiology, 2016
Biofilms develop rapidly following endotracheal intubation and represent a persistent source of unnecessary pathogens in the critically ill patient. Overall, the imbalance in the lung microbiome caused by an endotracheal tube and its role in biofilm formation and in ventilator-associated pneumonia is still unclear.
Laia, Fernández-Barat, Antoni, Torres
openaire   +2 more sources

Ventilator-associated pneumonia

Current Opinion in Pulmonary Medicine, 2005
This review summarises some of the notable papers on ventilator-associated pneumonia (VAP) from January 2003 to October 2004.Ventilator-associated pneumonia remains an important drain on hospital resources. All population groups are affected, but patients with VAP are more likely to be older, sicker, and male, with invasive medical devices in situ ...
openaire   +2 more sources

Prevention of ventilator-associated pneumonia

Current Opinion in Infectious Diseases, 2017
Purpose of review Ventilator-associated pneumonia (VAP) is an iatrogenic disease. Here we appraise recent advancements in the development and testing of strategies to prevent VAP. We also provide recommendations on the most promising interventions that should be applied. Recent findings
Li Bassi, Gianluigi, Senussi, Tarek, Aguilera Xiol, Eli   +2 more
openaire   +4 more sources